Abstract: The present invention provides methods of making an in vivo animal model for detecting anti-poly(ethylene glycol) (PEG) antibodies. The methods of the disclosure comprises administering subcutaneously to an animal model a composition comprising antibodies against poly(ethylene glycol) chains with a molecular weight of at least 550 Da to maintain an anti-PEG antibody level within the animal model. The in vivo animal model can be used for testing and screening drugs and other compositions for adverse reactions, bioavailability, and immunogenicity prior to administration to a human subject.

Abstract: Provided herein are methods, compositions, devices, and systems for the 3D printing of biomedical implants. In particular, methods and systems are provided for 3D printing of biomedical devices (e.g., endovascular stents) using photo-curable biomaterial inks (e.g., or methacrylated poly(diol citrate)).

Abstract: Provided herein are thermoresponsive polymer materials and methods of preparation and use thereof. In particular, materials are provided that cure upon exposure to physiologic conditions (e.g., human body temperature) and find use in, for example, orthopedic surgery, bone tissue engineering, and the repair of bone injuries and defects.

Abstract: Provided herein are injectable, thermoresponsive hydrogels that are liquid at room temperature, provide a carrier material, and gel at body temperature to allow for controlled release. In particular, PPCN-based hydrogels are provided with therapeutic agents (e.g., drugs, ions, etc.) incorporated within or appended thereto, and methods of preparation and use thereof, for example, for the promotion of bone formation/repair and/or the treatment of bone diseases.

Abstract: Provided herein are nanocarriers for delivery of immunosuppressive agents. In some embodiments, provided herein are nanocarriers comprising a core comprising a poly(ethylene glycol)-block-poly(propylene sulfide) copolymer and least one therapeutic agent. In some embodiments, the nanocarriers may further comprise a targeting ligand displayed on a surface of the nanocarrier. The at least one therapeutic agent may be an anti-inflammatory agent. The disclosed nanocarriers may be incorporated into pharmaceutical compositions for use in methods of treating an inflammatory condition or preventing transplantation rejection in a subject.

Abstract: Provided herein are methods, compositions, devices, and systems for the 3D printing of biomedical implants. In particular, methods and systems are provided for 3D printing of biomedical devices (e.g., endovascular stents) using photo-curable biomaterial inks (e.g., or methacrylated poly(diol citrate)).

Abstract: Provided herein are injectable, thermoresponsive hydrogels that are liquid at room temperature, provide a carrier material, and gel at body temperature to allow for controlled release. In particular, PPCN-based hydrogels are provided with therapeutic agents (e.g., drugs, ions, etc.) incorporated within or appended thereto, and methods of preparation and use thereof, for example, for the promotion of bone formation/repair and/or the treatment of bone diseases.

Abstract: Compositions and methods are provided for improved wound healing. In particular, provided herein are compositions and methods for the direct delivery of Sirtuin-1 (Sirt1) or vectors encoding Sirt1 to the wounds (e.g., of diabetic patients).

Abstract: Provided herein are materials and methods related to scaffolds and uses thereof. In some embodiments, provided herein are poly (octamethylene-octanol citrates) (POOC) scaffolds with native mechanical properties that are comparable to urinary bladder tissue. In some embodiments, provided herein are methods for the synthesis of POOC scaffolds with native mechanical properties that are comparable to urinary bladder tissue by including octanol in the polycondensation synthesis of POC. In some embodiments, provided herein are methods of use of the disclosed scaffolds, including for urinary bladder tissue regeneration.

Abstract: Provided herein is technology relating to anticoagulant therapies and particularly, but not exclusively, to anticoagulant compositions for localized and targeted administration and related methods and kits for treatment of a subject with a localized and targeted anticoagulant therapy.

Abstract: Provided herein photo-reactive inks, thermal-curable materials and objects (e.g., medical implants, scaffolds, devices, etc.) made therefrom, and methods of preparation and use thereof.

Abstract: The present invention provides methods for generating a mouse model that produces anti-polyethylene glycol (PEG) antibodies. Also provided are mice generated by said methods and methods of using these mice to screen PEG-containing products in vivo.

Abstract: Provided herein are compositions, devices, and systems comprising copolymers of an N-alkyl acrylamide residue and a polyester comprising citric acid, polyethylene glycol, and glycerol 1,3-diglycerolate diacrylate, and methods of use and manufacture thereof.

Abstract: Provided herein are methods, compositions, devices, and systems for the 3D printing of biomedical implants. In particular, methods and systems are provided for 3D printing of biomedical devices (e.g., endovascular stents) using photo-curable biomaterial inks (e.g., or methacrylated poly(diol citrate)).

Abstract: A medical swab includes a hollow tube shaft that has a distal end and a proximal end. A swab tip is mounted to the hollow tube shaft such that a first portion of the swab tip is positioned within the distal end of the hollow tube shaft and a second portion of the swab tip extends out from the distal end of the hollow tube shaft.

Abstract: Disclosed are heparin conjugates comprising heparin conjugated to a peptide that binds to a protein of the extracellular matrix (ECM) of cellular tissue, such as a collagen-binding peptide that binds to collagen of the ECM. The disclosed heparin conjugates may be utilized in methods that include treating ECM material to incorporate the heparin conjugates and impart anticoagulant activity to the ECM. The disclosed heparin conjugates also may be formulated as pharmaceutical compositions for treating and/or preventing vascular injuries and conditions.

Abstract: The present invention provides methods of making an in vivo animal model for detecting anti-poly(ethylene glycol) (PEG) antibodies. The methods of the disclosure comprises administering subcutaneously to an animal model a composition comprising antibodies against poly(ethylene glycol) chains with a molecular weight of at least 550 Da to maintain an anti-PEG antibody level within the animal model. The in vivo animal model can be used for testing and screening drugs and other compositions for adverse reactions, bioavailability, and immunogenicity prior to administration to a human subject.

Abstract: Provided herein photo-reactive inks, thermal-curable materials and objects (e.g., medical implants, scaffolds, devices, etc.) made therefrom, and methods of preparation and use thereof.

Abstract: Provided herein are intravascular retrievable cell delivery systems and methods of use thereof for cell transplantation.

Abstract: Provided herein are nanocarriers for delivery of immunosuppressive agents. In some embodiments, provided herein are nanocarriers comprising a core comprising a poly(ethylene glycol)-block-poly(propylene sulfide) copolymer and least one therapeutic agent. In some embodiments, the nanocarriers may further comprise a targeting ligand displayed on a surface of the nanocarrier. The at least one therapeutic agent may be an anti-inflammatory agent. The disclosed nanocarriers may be incorporated into pharmaceutical compositions for use in methods of treating an inflammatory condition or preventing transplantation rejection in a subject.